Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 12/20 | 0.50 |
| ▸ | CTSS | P25774 | 12/20 | 0.50 |
| ▸ | CTSL | P07711 | 11/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702276 | 0.77 | CTSK (0.63) | CTSBCTSSCTSLCTSKLMNA | |
| SCHEMBL5872414 | 0.75 | CTSL (0.48) | CTSBCTSSCTSLCTSKLMNA | |
| SCHEMBL4703896 | 0.67 | CTSB (0.70) | CTSBCTSSCTSLCTSKLMNA | |
| SCHEMBL6182464 | 0.67 | CTSK (0.64) | CTSBCTSSCTSLCTSK | |
| SCHEMBL4704596 | 0.67 | CTSB (0.57) | CTSBCTSSCTSLCTSKMAPK1 | |
| SCHEMBL6183485 | 0.67 | CTSB (1.00) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6182475 | 0.67 | CTSS (0.62) | CTSBCTSSCTSLCTSKMAPT | |
| SCHEMBL4714054 | 0.67 | CTSK (0.92) | CTSBCTSSCTSLCTSK | |
| SCHEMBL12632188 | 0.66 | SMN1; SMN2 (0.53) | CTSBCTSSCTSLCTSKLMNA | |
| SCHEMBL12670720 | 0.66 | LMNA (0.60) | CTSBCTSSCTSLCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSB 1/4885CTSS 2/4885CTSL 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.